Indiana's Harlan Laboratories has struck up a deal with French CRO Bertin Pharma to pool resources on early development, teaming up to offer drug discovery and translational medicine services.
BSD Medical said Terumo will distribute one of its key ablation surgical tools into Eastern European markets and the Middle East over the coming months, expanding on a fledgling partnership that has already demonstrated some traction in other European, Western Asian and African countries.
CRO Charles River Laboratories has selected Exostar to serve as the gatekeeper to its data, tasking the cloud-based service provider with securing its proprietary information.
Medtronic and Abbott have collaborated on a discount deal that makes the two stent giants preferred vendors for the costly medical devices at 135 U.S. hospitals.
Netherlands' CRO Cardialysis has reached out to Boston eClinical outfit AG Mednet to oversee data submission and collection for the medical device and drug trials it runs at more than 1200 sites around the world.
Galapagos NV's collaboration with GlaxoSmithKline has hit a roadblock. Late last week the Belgian biotech reported that its Big Pharma partner had hit the brakes on a Phase II study of GSK2586184 for lupus after a first look at the data failed to demonstrate a positive effect.
MPI Research and its CRO partners are a couple months away from cutting the ribbon on their imaging-focused collaboration, and now the three have installed the particle accelerator they say they'll need to stand out among other drug researchers.
As demand for biosimilar development swells around the world, CRO inVentiv Health has teamed up with Australia's Proteomics International to expand its characterization services, an effort to boost its capabilities in early work on biologic knockoffs.
After largely abandoning the field back in 1999, Roche is diving back into antibiotics, teaming up with Cambridge, U.K.'s Discuva to discover and develop new treatments for deadly infections using the biotech's novel platform.
There's no word on the upfront, but Sanofi has committed to pay up to $198 million in milestones if the portfolio delivers an approved therapy that can be used to treat hyperphosphatemia, a condition characterized by elevated levels of phosphate in the blood of patients with end stage renal disease and other forms of chronic kidney disease.